Use of angiotensin-converting enzyme inhibitors or receptor blockers is associated with reduced mortality in patients with post-acute kidney injury: meta-analysis.

ABSTRACT

OBJECTIVE: To investigate the association between the use of ACEis or ARBs and outcomes in patients recovering from AKI. MATERIALS AND METHODS: We searched PubMed, MEDLINE, Cochrane Database, Web of Science and Embase databases from inception to May 2021 and performed a systematic review and meta-analysis using the "meta" package in R 4.0.3. RESULTS: Five cohort studies, published from 2018 to 2021 with 153174 participants and approximately 39081 mortalities, were included in our meta-analysis. The meta-analysis showed that the use of ACEis/ARBs in patients with post-AKI is associated with a significantly lower risk of death (HR 0.80; 95% CIs, 0.72-0.90) and subgroup analysis showed a significant result in ACEi/ARB users with over 1-year of follow-up (HR 0.86; 95% CIs, 0.77-0.95). CONCLUSIONS: The use of ACEi/ARB in patients with post-AKI is associated with a significantly lower risk of death.